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Abstract
Kawasaki disease (KD) is a pediatric vasculitis that damages the coronary arteries in 25% of untreated and approximately 5%
of treated children. Epidemiologic data suggest that KD is triggered by unidentified infection(s) in genetically susceptible
children. To investigate genetic determinants of KD susceptibility, we performed a genome-wide association study (GWAS)
in 119 Caucasian KD cases and 135 matched controls with stringent correction for possible admixture, followed by
replication in an independent cohort and subsequent fine-mapping, for a total of 893 KD cases plus population and family
controls. Significant associations of 40 SNPs and six haplotypes, identifying 31 genes, were replicated in an independent
cohort of 583 predominantly Caucasian KD families, with NAALADL2 (rs17531088, pcombined = 1.13610
26) and ZFHX3
(rs7199343, pcombined = 2.37610
26) most significantly associated. Sixteen associated variants with a minor allele frequency of
.0.05 that lay within or close to known genes were fine-mapped with HapMap tagging SNPs in 781 KD cases, including 590
from the discovery and replication stages. Original or tagging SNPs in eight of these genes replicated the original findings,
with seven genes having further significant markers in adjacent regions. In four genes (ZFHX3, NAALADL2, PPP1R14C, and
TCP1), the neighboring markers were more significantly associated than the originally associated variants. Investigation of
functional relationships between the eight fine-mapped genes using Ingenuity Pathway Analysis identified a single
functional network (p= 10213) containing five fine-mapped genes—LNX1, CAMK2D, ZFHX3, CSMD1, and TCP1—with
functional relationships potentially related to inflammation, apoptosis, and cardiovascular pathology. Pair-wise blood
transcript levels were measured during acute and convalescent KD for all fine-mapped genes, revealing a consistent trend of
significantly reduced transcript levels prior to treatment. This is one of the first GWAS in an infectious disease. We have
identified novel, plausible, and functionally related variants associated with KD susceptibility that may also be relevant to
other cardiovascular diseases.
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Introduction
Kawasaki disease (KD; MIM 611775) is an inflammatory
vasculitis predominantly affecting young children [1]. It is
characterized by a striking propensity for coronary artery damage,
which occurs in approximately 25% of untreated and 3–5% of
treated children. KD is the commonest cause of heart disease
acquired in childhood in developed nations and in those who
manifest coronary artery damage, KD may be associated with
serious cardiovascular sequelae in adulthood [2]. The long-term
cardiovascular implications of KD in those without overt coronary
artery lesions are unclear. The etiology of KD is unknown, but it is
thought to reflect an abnormal and sustained inflammatory
response to one or more infectious triggers in genetically
susceptible individuals [1,3]. No consistent etiologic agent for
KD has been identified, hampering accurate and timely diagnosis
and the development of optimal management strategies.
The incidence of KD varies markedly in different ethnic groups,
with the highest incidence in North East Asian populations. KD
affects approximately 1 in 150 Japanese children [1] and is
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responsible for 1–2% of all pediatric hospital admissions in South
Korea [4]. There are strong epidemiologic data to support a
substantial genetic contribution to KD susceptibility. The Japanese
incidence (135–200/100 000,5 years of age) is 10–15 times
greater than the Caucasian incidence (9–17/100 000,5 years of
age) [1] and this difference is maintained in American children of
Japanese descent resident in the US [5]. Other Asian populations
in the UK [6,7] and the US [8] also have a significantly higher
incidence than non-Asians residing in the same geographic
location. The familial inheritance pattern of KD is in keeping
with a polygenic complex disease and in multi-case pedigrees, KD
occurs in family members at different times and geographic
locations [9]. Across all populations KD is approximately 1.6 times
more common in males [3]. The sibling risk ratio for KD in the
Japanese is approximately 10 during an epidemic [10] and 6
overall [11]. KD is over twice as common in the children of
parents who themselves had KD in childhood, with multi-
generational pedigrees often having more than one child affected,
an earlier age of onset and a more severe phenotype [11].
A genome-wide linkage study identified three regions exhibiting
modest linkage in Japanese KD sibling pairs [12]. Detailed
association analysis of the linkage peak at chromosome 19q13.2
identified a significantly associated functional variant in ITPKC
(Gene ID:80271), a negative regulator of T cell activation [13]. In
both Japanese and US Caucasian children with KD, this variant
was associated with an approximate doubling of KD risk [13].
Other investigations of KD susceptibility determinants to date have
been candidate gene association studies. A number of immunologic
and cardiovascular-related loci have revealed genetic associations of
modest effect size, but studies have often been under-powered and
the findings have rarely been replicated in independent populations.
As these associated candidate loci are likely to account for only a
small proportion of the overall genetic susceptibility to KD, we
undertook a genome-wide association study (GWAS) to identify
novel loci that might mediate susceptibility to KD. We performed
the initial GWAS in a well-characterized Dutch Caucasian
population and tested the most significantly associated SNPs and
haplotypes in a large independent cohort of predominantly
Caucasian trios from three countries. Fine-mapping of sixteen
variants with a minor allele frequency (MAF) of .0.05 that lay
within or close to known genes identified eight significantly
associated variants, five of which may be functionally related.
Results
Genome-Wide Association Study
We included 119 KD cases and 135 controls in the initial
GWAS (Table 1). Ten non-Caucasian subjects were excluded
following admixture analysis by Eigenstrat [14]. Three samples
were excluded due to genotyping call rates,93%. The final GWA
analysis therefore consisted of 107 KD subjects and 134 controls.
Of the 262,264 SNPs on the Affymetrix 250 K NSP chip, 18,211
had a call rate of ,93%, 18,981 were monomorphic
(MAF,0.1%) and 1,150 deviated significantly from HWE in the
control group. 223,922 SNPs were therefore available for analysis,
of which 5,571 were on the X chromosome. A total of 14,065
SNPs were significantly associated (p,0.05). The quantile-quantile
plot between observed and expected allele frequencies showed
deviation from expected with p,,1024, suggesting the presence
of true associations [15] (Figure 1).
Follow-Up Replication Study in Independent Cohorts
We undertook a replication study in an independent cohort of
KD cases and parental controls, using an exact replication
strategy, genotyping only the most significantly associated variants
by a different genotyping technology. After verifying family
relationships and checking sample duplications, 63 samples were
excluded from further analysis. Thus 1,903 members of 583 KD
families, including 498 trios, were tested in the follow-up
association analysis.
Author Summary
Kawasaki disease is an inflammatory pediatric condition
that damages the coronary arteries in a quarter of
untreated patients and is the commonest cause of
childhood acquired heart disease in developed countries.
While the infectious trigger(s) remain unknown, epidemi-
ologic evidence suggests that human genetic variation
underlies the susceptibility. In order to identify novel
mechanisms that may predispose to this disease, we
undertook a genome-wide association study, which
investigates genetic determinants without prior supposi-
tion regarding the loci of interest. This was amongst the
first complex infectious diseases to be studied in this way
and one of the largest genetic studies of Kawasaki disease
with 893 cases. We identified and confirmed 40 SNPs and
six haplotypes, identifying 31 genes, in an international
cohort of Caucasian patients. We followed up 16 SNPs
where the associated genetic variant was more common
and was situated within a gene, confirming eight SNPs by
fine-mapping across the entire gene. Of these eight genes,
seven were expressed in blood and five showed signifi-
cantly different gene expression in paired patient samples
taken during acute and convalescent Kawasaki disease.
Five of the eight genes also appear to be involved in a
single putative functional network of interacting genes.
These novel genes and pathways may ultimately lead to
novel diagnostics and treatment for Kawasaki disease.
Table 1. Demographic and Clinical Characteristics of Subjects in the GWAS (Dutch Case-Control Samples) and Replication Study
(Australian, US And UK Families).
Characteristics Genome-Wide Association Cohort Family-based Follow-up Cohort
Cases (% male) 119 (58.8) 583 (63.1)
Controls (% male) 135 (63.8) 1357 (48.8) a
Caucasian ethnicity (%) 241/254 (94.5) -
Coronary artery abnormalityb (%) 27/119 (22.7) 155/583 (26.5)
aparents and healthy siblings of proband.
bsignificant coronary dilatation on any echocardiogram during the KD illness.
doi:10.1371/journal.pgen.1000319.t001
Genome-Wide Association Study of Kawasaki Disease
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Replication of Individual SNP Associations
The 1,148 most significantly associated SNPs variants (corre-
sponding to a minimum significance level of p,0.0024) were
selected by a combination of Armitage trend test, recessive-
dominant and allelic association analysis (Figure 2). SNPs were
genotyped in the follow-up cohort by a custom Illumina Oligo Pool
Assay, in which 1,116 SNPs were successfully genotyped (Table S1).
Fifteen SNPs failed quality filters, leaving a total of 1,101 SNPs.
Significant associations with KD susceptibility were replicated
for 40 SNPs (Table 2). Twenty eight lay either in or within 50 kb
of known genes. The most highly associated SNP was located in
the gene for N-acetylated alpha-linked acidic dipeptidase-like 2
(NAALADL2, Gene ID:254827), (combined OR from case-control
and family analyses = 1.43 (1.32–1.53); pcombined = 1.13610
26).
Three SNPs were located in introns of the gene for AT-binding
transcription factor 1 (ZFHX3, Gene ID:463), all of which had a
protective effect (ORcombined = 0.64 (0.52–0.75), 0.68 (0.57–0.79),
0.73 (0.62–0.84); pcombined = 2.37610
26, 7.0661025, 5.3561024,
respectively). Two of these SNPs, rs7199343 and rs10852516,
were only 647 bp apart and in high linkage disequilibrium (LD)
(r2 = 0.93), whereas the third SNP, rs11075953, was ,10 kb
distant and in less LD (r2 = 0.46). Two SNPs, rs1010824 and
rs6469101, which were 325 bp apart and in complete LD (r2 = 1),
were situated ,10 kb 39 of the angiopoietin 1 gene (ANGPT1,
Gene ID:284) (ORcombined = 0.58 (0.43–0.73) and 0.6 (0.45–0.76);
pcombined = 3.39610
25 and 5.4461025, respectively).
Replication of Haplotypic Associations
166 SNPs within the most highly associated thirty five haplotype
blocks (corresponding to p,261023) were genotyped using a
Sequenom iPLEX platform in the replication cohort (Table S2).
Twenty-nine SNPs could not be genotyped, leaving 137 SNPs for
further analysis. Significant associations were verified for six
haplotypes, of which four were within known genes. Two
haplotypes lay within the gene encoding M-phase phosphoprotein
10 (U3 small nucleolar ribonucleoprotein), MPHOSPH10 (Gene
ID:10199). One of these haplotypes was associated with increased
susceptibility (ORcombined = 3.52 (1.6–7.75); p = 3.69610
23) and
the other with protection from KD (ORcombined = 0.39 (0.24–0.63);
p = 3.9161024) (Table 2).
Fine-Mapping of More Common Associated Variants
Lying within or Close to Known Genes
In order to narrow the region of association within selected genes,
we carried out fine-mapping of sixteen of the genes replicated in the
family study (Table S3). We fine-mapped genes identified by
variants with a MAF of .0.05 lying within 5 kb of known genes.
Polymorphisms from eight of the sixteen fine-mapped genes showed
significant combined p-values (Table 3). In three genes the tagging
SNP showed the most significant genetic association; LNX1
(Gene ID:84708) (rs7660884, pcombined = 1.8610
23), CAMK2D
(Gene ID:817) (rs11728021, pcombined = 1.3610
22) and CSMD1
(Gene ID:64478) (rs2912272, pcombined = 3.5610
22), indicating that
the initial GWAS probably identified a disease-associated haplo-
type. Conversely within NAALADL2, the most significantly associ-
ated gene identified in the replication study, a polymorphism
(rs1870740) located 23 kb away from the tagging SNP (rs2861999)
was the most significantly associated (pcombined = 9610
24). A linkage
disequilibrium plot of this region indicated that these two SNPs
belong to distinct haplotype blocks (Figure 3). The transcription
factor ZFHX3 had a number of SNPs with more significant
associations than the variant tagging the replicated polymorphism
(Figure S2). Linkage disequilibrium plots of all fine-mapped genes
are presented in the online supplemental material (Figure S3, S4,
S5, S6, S7, and S8).
Allele Frequencies in Different Ethnic Groups and
Identification of the Ancestral Allele
In order to investigate differences in allele frequencies of associated
SNPs between Japanese, where the incidence of KD is approximately
twenty times higher than that of Caucasians, we comparedMAF data
for associated variants usingHapMap. In addition we investigated the
ancestral allele of each associated SNP from available data from
higher primates (Chimpanzee andMacaque) (Table S4). All (but one)
associated alleles of SNPs within ZFHX3 had higher frequencies in
the Japanese population. The associated allele (T) from the most
Figure 2. Selection and Verification of SNPs And Haplotypes
from the GWAS Analysis. GWAS SNPs and haplotypes were ranked
by P-value and the top 1101 (of 14,065 total associated) SNPs and 35 (of
3,549 non-overlapping total associated) haplotypes were carried
through to the follow-up stage. Numbers in parenthesis indicate the
number of variants selected from the GWAS by each method of
selection that were subsequently replicated in the family-based study.
doi:10.1371/journal.pgen.1000319.g002
Figure 1. Quantile-Quantile Plot of Allelic Distributions. Allelic
association analysis of expected versus observed P-values of 223,922
SNPs in 107 KD cases and 134 controls. Red dots showing deviations
from the line of equality indicate either that the theoretical distribution
was incorrect, or that the sample was contaminated with values
generated by a true association.
doi:10.1371/journal.pgen.1000319.g001
Genome-Wide Association Study of Kawasaki Disease
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Table 3. Combined P-Values of Fine-Mapped Genes.
Case-control Family-based
Marker Chr Gene
Allelic
p value ORs(95%CI) p value ORs(95%CI)a Info.famb
Combined
p value Location Consequence
rs6801807 3 NAALADL2 0.51 0.89(0.63–1.25) 3.8*1023 0.77(0.64–0.93) 275 1.3*1022 176150140 UPSTREAM
rs9813316 3 NAALADL2 0.31 0.81(0.55–1.2) 1.8*1022 0.77(0.63–0.94) 234 3.4*1022 176191353 UPSTREAM
rs6806492 3 NAALADL2 0.36 0.83(0.56–1.2) 1.9*1023 0.70(0.57–0.87) 226 5.6*1023 176193394 UPSTREAM
rs7651836 3 NAALADL2 0.27 0.83(0.59–1.15) 1*1022 0.88(0.73–1.06) 289 2*1022 176344378 INTRONIC
rs9881727 3 NAALADL2 0.51 0.90(0.66–1.21) 9.8*1023 0.85(0.71–1.02) 325 3.1*1022 176344679 INTRONIC
rs1870740 3 NAALADL2 0.38 0.88(0.65–1.17) 2.2*1024 0.75(0.64–0.89) 341 9*1024 176364140 INTRONIC
rs1381126 3 NAALADL2 0.07 0.66(0.42–1.02) 0.07 0.74(0.58–0.96) 187 3.4*1022 176369549 INTRONIC
rs13062041 3 NAALADL2 0.51 0.90(0.68–1.21) 1.2*1022 0.83(0.70–0.99) 337 3.7*1022 176377638 INTRONIC
rs2035101 3 NAALADL2 0.65 1.07(0.8–1.44) 3.7*1024 1.31(1.11–1.57) 330 2.2*1023 176378534 INTRONIC
rs2861999c 3 NAALADL2 0.31 1.17(0.87–1.56) 8.3*1023 1.23(1.04–1.46) 335 1.8*1023 176387101 INTRONIC
rs7615453 3 NAALADL2 0.3 0.84(0.62–1.15) 1.7*1022 0.83(0.70–1.00) 313 3.3*1022 176392646 INTRONIC
rs6788338 3 NAALADL2 3.5*1022 0.72(0.53–0.97) 0.07 0.95(0.80–1.13) 311 1.8*1022 176538191 INTRONIC
rs17082951 4 LNX1 0.98 1.00(0.73–1.39) 7*1023 1.24(1.03–1.50) 304 4.1*1022 54087872 INTRONIC
rs6554112 4 LNX1 1.1*1022 1.50(1.10–2.03) 0.5 1.04(0.87–1.25) 296 3.6*1022 54113392 INTRONIC
rs7660884c 4 LNX1 1.1*1022 1.77(1.15–2.74) 1.7*1022 1.51(1.14–2.00) 152 1.8*1023 54121365 INTRONIC
rs4834340 4 CAMK2D 0.24 0.84(0.62–1.12) 1.7*1022 0.86(0.72–1.02) 297 2.7*1022 114620118 INTRONIC
rs11728021c 4 CAMK2D 0.28 1.23(0.85–1.76) 6.6*1023 1.23(0.98–1.52) 232 1.3*1022 114698102 INTRONIC
rs1408504 6 PPP1R14C 4.8*1022 0.70(0.55–0.99) 1.1*1022 0.86(0.73–1.02) 337 4.4*1023 150513287 INTRONIC
rs12332856c 6 PPP1R14C 1.3*1022 0.64(0.45–0.9) 0.22 0.88(0.72–1.08) 242 2*1022 150514181 INTRONIC
rs2144400 6 PPP1R14C 0.42 0.86(0.59–1.23) 5.3*1023 0.79(0.63–0.98) 222 1.5*1022 150547398 INTRONIC
rs2295899c 6 TCP1 0.09 0.77(0.58–1.03) 0.09 0.85(0.72–1.01) 315 4.7*1022 160122157 INTRONIC
rs3818298 6 TCP1 0.23 0.78(0.52–1.15) 1.9*1022 0.75(0.60–0.92) 244 2.8*1022 160126706 INTRONIC
rs10215596 7 DGKB 0.18 0.69(0.4–1.17) 2.5*1022 0.82(0.61–1.11) 133 2.9*1022 14326534 INTRONIC
rs12699612 7 DGKB 0.69 1.07(0.76–1.51) 2*1023 0.8(0.66–0.96) 299 1.1*1022 14388440 INTRONIC
rs196751d 7 DGKB 2.5*1022 0.71(0.53–0.95) 0.1 0.88(0.74–1.03) 311 1.8*1022 14443632 INTRONIC
rs1431518 7 DGKB 0.08 0.62(0.36–1.06) 0.06 0.72(0.53–0.99) 113 3.4*1022 14458033 INTRONIC
rs1367782 7 DGKB 0.06 0.75(0.56–1.01) 0.12 0.87(0.73–1.02) 322 4.6*1022 14560761 INTRONIC
rs1431513 7 DGKB 8.2*1023 1.50(1.12–2.00) 0.84 1.03(0.87–1.22) 310 4.1*1022 14571423 INTRONIC
rs6949687 7 DGKB 9*1023 0.67(0.5–0.9) 0.21 0.88(0.74–1.04) 329 1.4*1022 14577139 INTRONIC
rs1404611 7 DGKB 3.2*1022 0.63(0.42–0.95) 0.12 0.83(0.65–1.06) 176 2.5*1022 14638173 INTRONIC
rs2912272d 8 CSMD1 9.7*1022 1.55(0.93–2.57) 0.06 1.5(1.10–2.06) 124 3.5*1022 3885737 UPSTREAM
rs8055870 16 ZFHX3 0.11 0.78(0.58–1.05) 0.05 0.9(0.76–1.07) 347 3.7*1022 71529591 INTRONIC
rs7193297 16 ZFHX3 1.2*1022 0.68(0.51–0.91) 0.35 1.00(0.84–1.19) 311 3.7*1022 71551332 Ser72Ala
rs4788683 16 ZFHX3 7.2*1024 0.59(0.44–0.79) 0.31 0.96(0.80–1.14) 312 2.1*1023 71555248 INTRONIC
rs11075953c 16 ZFHX3 1.2*1022 0.67(0.49–0.9) 1.1*1022 0.82(0.68–0.97) 299 1.3*1023 71557266 INTRONIC
rs9921395 16 ZFHX3 0.07 0.76(0.56–1.02) 8.4*1024 0.77(0.65–0.91) 319 6.8*1024 71559458 INTRONIC
rs9937546 16 ZFHX3 0.07 0.75(0.55–1.02) 2*1024 0.72(0.60–0.87) 284 1.9*1024 71561220 INTRONIC
rs12445917 16 ZFHX3 7.8*1023 0.61(0.42–0.86) 7.8*1023 0.76(0.61–0.94) 226 6.6*1024 71562038 INTRONIC
rs11075954 16 ZFHX3 0.95 1.00(0.74–1.32) 3.6*1023 1.26(1.06–1.49) 310 2.3*1022 71569665 INTRONIC
rs11640395 16 ZFHX3 6.8*1023 0.61(0.42–0.86) 3.3*1022 0.82(0.67–1.02) 225 2.1*1023 71572247 INTRONIC
rs17681554 16 ZFHX3 2.2*1022 0.70(0.52–0.94) 1*1023 0.78(0.66–0.92) 317 2.7*1024 71574269 INTRONIC
rs17692597c 16 ZFHX3 1.3*1022 0.67(0.49–0.91) 1.2*1022 0.86(0.71–1.03) 290 1.5*1023 71579774 INTRONIC
rs7193343 16 ZFHX3 1.5*1023 0.52(0.36–0.78) 0.11 0.8(0.65–1.00) 222 1.5*1023 71586661 INTRONIC
rs11075958 16 ZFHX3 1.3*1022 0.63(0.44–0.9) 0.08 0.87(0.70–1.08) 204 8.5*1023 71591370 INTRONIC
rs719353 16 ZFHX3 2.8*1023 0.63(0.47–0.85) 0.38 0.90(0.76–1.06) 331 8.5*1023 71600052 INTRONIC
rs4788694 16 ZFHX3 5.9*1023 0.66(0.5–0.88) 0.88 0.96(.082–1.14) 313 3.2*1022 71627584 INTRONIC
aHaplotype relative risk odds ratio.
bNumber of informative families.
ctagging SNP.
dsame SNP typed (from GWAS and follow up).
doi:10.1371/journal.pgen.1000319.t003
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significantly associated SNP (rs9937546 pcombined=1.9610
24), had
an allele frequency of 0.922 in the Japanese, compared to 0.633 in
Caucasians. Despite the high frequencies in human populations, the
rs9937546 T allele was not the ancestral allele, which might indicate
rapid fixation in the population due to an unidentified evolutionary
advantage. In contrast the associated allele of rs2912272 from
CSMD1, was absent in Japanese populations, which could indicate
genetic heterogeneity in this gene, with other variants associated with
susceptibility in the Japanese. In CSMD1 the ancestral allele is the
major allele in humans.
Gene Network Analysis
We explored possible functional relationships between the eight
genes confirmed by fine-mapping using the Ingenuity Pathway
Analysis (IPA) Knowledge Base. Unsupervised IPA network analysis
identified a single cluster of 35 genes that included five of the eight
associated genes and 26 additional genes, that was unlikely to
occur by chance (p = 10213). Highlights from the group are shown
in Figure 4, concentrating on the close connection between four of
the associated fine-mapped genes and eight IPA identified genes
that create a plausible biological network.
Gene Expression
We investigated the whole blood transcript levels of the eight
fine-mapped associated genes, and three of the IPA identified
genes, using TaqMan quantitative PCR, in 27 patients with paired
samples from their acute KD stage (prior to treatment) and their
convalescence, using the transcript levels of the gene 18S as a
Figure 3. Linkage Disequilibrium Plot of a Region of NAALADL2 Containing the Most Significantly Associated Variants. The upper
portion shows -log (p-values) of tagging SNPs (r2.0.8) of the polymorphisms, initially identified in our GWAS (rs2861999) and replication study
(rs17531088), which are highlighted in blue. D9 values are shown inside each diamond. Red diamonds without a number represent D9= 1.
doi:10.1371/journal.pgen.1000319.g003
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loading control. The blood cell profiles of these patients have been
described previously [16]. Of the 54 RNA samples, two pairs were
excluded because of inadequate RNA quality.
Of the eight GWAS identified genes, five showed significantly
lower abundance at the acute phase compared to convalescence,
while two showed no change and expression of one was not
detected in peripheral blood (Table 4). For the three IPA identified
genes investigated, one showed significantly higher abundance,
one showed significantly lower abundance and one showed no
significant difference between acute and convalescence samples
(Table 4). NAALADL2 (NM_207015) showed the largest fold
change (FC) (FC=26.3, p = 1.5561024), while CAMK2D
(NM_001221) showed the most significant difference
(FC=22.5, p = 1.5361027) (Table 4). Relative transcript abun-
dance is represented in the network diagram (Figure 4), with red
indicating greater abundance in acute samples compared to
convalescent samples, green lower abundance and yellow no
change.
Discussion
To our knowledge, this is among the first GWAS of an
infectious disease and the first GWAS of KD. We have identified a
number of novel variants using a staged study design and
subsequent fine-mapping that are associated with KD susceptibil-
ity. These include variants within or close to genes that are
functionally inter-related and that are plausible biological
candidates in the KD pathogenesis. The magnitude of the effect
sizes for KD susceptibility is comparable to that reported from
other GWAS [17]. Fine-mapping of associated and replicated
SNPs has focused on more frequent variants that lie in known
genes. In eight of these sixteen genes, fine-mapping confirmed the
association and identified one or more associated haplotype(s),
which will form the basis of resequencing to identify the disease-
modifying variants.
The assertion that these variants are in (or close to) biologically
relevant loci involved in KD susceptibility is supported by; (i)
identification of eight loci containing one or more independently
associated haplotypes identified by GWAS, replicated in an
independent family-based study and subsequently fine-mapped,
(ii) the significant differential gene mRNA transcript abundance of
5 of the 7 blood-expressed fine-mapped genes during acute versus
convalescent KD, and (iii) the gene network analyses that suggest
biologically plausible functional relationships, which are extremely
unlikely to have occurred by chance, exist between five of the
associated loci.
We focused on fine-mapping of associated SNPs that lie either
in or within 5 kb of known genes and had a MAF of .0.05 in
HapMap. These data represent the most robust associations and
we will therefore focus our discussion on those genes, where
putative functional relationships were suggested by IPA. We used
IPA in an unsupervised manner, allowing identification of gene-
Figure 4. Putative Gene Network Derived from Ingenuity Pathway Analysis Software. Edges are displayed with labels that describe the
nature of the relationship between the nodes. The lines between genes represent known interactions, with solid lines representing direct interactions
and dashed lines representing indirect interactions. Nodes are displayed using various shapes that represent the functional class of the gene product
(see legend). Blue highlighting indicates GWAS associated genes and non-highlighted genes are those identified by IPA. Genes which showed
differential transcript levels in acute versus convalescent KD are colored red if the level was significantly higher during acute KD, green if the level was
significantly lower and yellow if there was no significant change, with color intensity related to fold change. Genes not colored were not measured.
doi:10.1371/journal.pgen.1000319.g004
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gene relationships without a priori assumptions. This analysis linked
five of the eight genetically associated genes, of which four form a
functionally closely related network linked to eight other nodes in a
highly significant network. The gene network suggests possible
mechanisms by which one or more infectious triggers may lead to
dysregulated inflammation and apoptosis, and cardiovascular
pathology.
Central to the putative gene network is CAMK2D (calcium/
calmodulin-dependent protein kinase (CaM Kinase) II delta),
whose expression was significantly down regulated during acute
KD. CAMK2D encodes the d-isoform of CaM kinase II
(NP_001212), a ubiquitously expressed calcium sensitive serine/
threonine kinase. The d-isoform of CaM kinase II is the
predominant form expressed in cardiomyocytes and vascular
endothelial cells [18] and is involved in a number of pathophys-
iological processes that make it an attractive candidate in KD. In
vascular endothelial cells CaM kinase II mediates nitric oxide
(NO) production by endothelial synthase (NOS3, NP_000594) in
response to changes in intracellular calcium and NO causes local
vasodilatation [18]. In acute KD NO production is increased and
NO metabolites decrease following successful treatment [19].
Following KD, especially where there has been overt CA damage,
there is endothelial dysfunction and impaired vasodilatation,
which can be restored after administration of antioxidants that
may increase local availability of NO [20]. More chronically,
NOS3 may become dysregulated (‘uncoupled’) and produce
potentially harmful superoxide anions, resulting in chronic oxidant
stress that is implicated in the pathogenesis of atherosclerosis [21].
In those with severe KD, NOS3 is expressed in coronary artery
aneurysm tissue removed at surgery, and the tissue shows a pattern
of senescence that is also typical of atherosclerosis [22].
Involvement of leukocyte expressed CaM kinase II in blood
vessel damage and aneurysm formation, key features of KD, is also
plausible. In human monocytes, CaM kinase II modulates tumor
necrosis factor-induced expression of CD44 (NP_000601), which
has a central role in leukocyte migration and extravasation at
inflammatory sites [23]. CaM kinase II is also involved in
disruption of the endothelial barrier following stimulation with
agonists such as thrombin [24], whose levels may be increased
following KD [25]. Disruption of barrier integrity in coronary
arteries may contribute to leukocyte infiltration into the vessel wall,
proteolysis of extracellular matrix proteins and the internal elastic
lamina and subsequent coronary artery aneurysm formation, that
is pathognomonic of KD [1].
In addition, CaM Kinase II regulates endotoxin- and TNF-
mediated apoptosis in human promonocytic cells by regulating the
anti-apoptotic gene BIRC3 (Gene ID:330)[26]. Delayed apoptosis
of leukocytes is characteristic of acute KD and may contribute to
pathogenesis [27]. Intravenous immunoglobulin (IVIg), standard
therapy for KD, induces apoptosis of neutrophils in acute KD
[28]. In a genome-wide transcriptional study of KD, there was a
marked over-representation of apoptosis regulatory genes [16].
Both CaM Kinase II and the product encoded by another fine-
mapped gene LNX1, i.e. ligand of numb-protein X1 (NP_116011),
interact with the NUMB family of proteins [29,30]. Interestingly,
one of the NUMB family members, NUMBL (numb homolog
(Drosophila)-like, Gene ID:9253) lies in the same small haplotype
block that has recently been associated with KD susceptibility by a
linkage study and subsequent fine-mapping [12,13]. The NUMB
gene (Gene ID:8650) showed significantly higher transcript
abundance during acute KD.
Both LNX1 and LNX2 (Gene ID:222484) (a closely related gene
identified by the IPA network) encode proteins that bind the
coxsackievirus and adenovirus receptor (CXADR, Gene ID:1525)
[31]. CXADR is the receptor for coxsackievirus B3, which causes
myocarditis in humans. The myocarditis can be prevented in
animal models by antagonizing viral binding to CXADR
(NP_001329.1) [32]. Coxsackievirus B3 has also been implicated
in acute myocardial infarction [33]. Interestingly, the human
endogenous retrovirus K protein Np9 also interacts with LNX1
[34] and therefore a number of viruses may theoretically bind the
NUMB/CAR/LNX1 complex, leading to internalization and
Table 4. Differential Gene Transcript Levels in Acute versus Convalescent KD.
Gene Name Transcript ID Sourcea
Acute KD median
RQ (S.D)
Convalescent
KD median RQ (S.D)
Differential transcript
levels Fold Change
CAMK2D NM_001221 GWAS 1.97(1.64) 5.00(1.89) 1.530E-07 22.5
CSMD1 NM_015336 GWAS 0.11(0.06) 0.20(0.39) 1.20E-03 21.8
DGKB NM_145695 GWAS Not detected Not detected - -
LNX1 NM_032622 GWAS 0.10(0.58) 0.17(10.07) 3.05E-02 21.7
NAALADL2 NM_207015 GWAS 0.16(0.67) 1.00(1.75) 1.55E-04 26.3
PPP1R14C NM_030949 GWAS 1.52(2.72) 1.94(3.15) - -
TCP1 NM_030752 GWAS 1.34(1.13) 2.41(1.26) 9.86E-03 21.8
ZFHX3 NM_006885 GWAS 1.20(0.72) 1.61 (2.9) - -
CAMK1D NM_153498 I 1.07(0.53) 1.37(0.46) - -
LNX2 NM_153371 I 1.38(0.66) 1.92(0.69) 7.35E-04 21.4
NUMB NM_001005743 I 0.64(0.31) 0.29(0.12) 9.82E-05 2.2
18s Endogenous Control C Ct = 13.64(0.19) Ct = 13.55(0.12) - -
aGWAS= genome wide association study identified genes that were successfully fine-mapped.
I = genes identified by Ingenuity Pathway Analysis; C = control; - =Not significant.
Transcript levels of eight fine-mapped genes and three genes suggested by Ingenuity Pathway Analysis (I) were compared to transcript abundance of the loading
endogenous control gene 18S, (C) in paired acute (prior to IVIg treatment) and convalescent KD samples from the same individuals (n = 25). Numbers are median (S.D.)
relative values compared to endogenous control and fold change (FC) calculated by median acute levels divided by median convalescent levels. For the 18S control,
numbers represent the mean (S.D.) PCR cycle at detection (Ct). Significance of differential transcript levels was determined using the Wilcoxon Rank Sum Test. - = not
significant.
doi:10.1371/journal.pgen.1000319.t004
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regulation of CAMK2D activity. This suggests a possible
mechanism whereby more than one infectious trigger may result
in cardiovascular damage in genetically susceptible individuals
suffering from KD.
Other fine-mapped IPA-networked genes include ZFHX3 (also
known as ATBF1), which encodes a large enhancer-binding
transcription factor that is known to be polymorphic [35] and
interacts with a number of proteins, including PIAS3 (protein
inhibitor of activated STAT, NP_006090) that inhibits STAT3
(signal transducer and activator of transcription-3, NP_644805) [36].
STAT3 is activated by interleukin 6 (IL6, NP_000591) a pro-
inflammatory cytokine that is involved in early innate immune
reactivity, as indicated by the high fever, acute phase response with
increased levels of CRP (NP_000558), complement factors and
fibrinogen, in the blood as well as the myriad of cellular markers
altered in acute KD [37]. ZFHX3 also interacts with MYH7 (myosin,
heavy chain 7, cardiac muscle, beta, NP_000248), in whichmutations
are known to cause an inherited form of cardiomyopathy [38].
CSMD1 (CUB and Sushi multiple domains 1), which is functionally
related to CaM kinase II via histone deacetylase 4 (HDAC4, Gene
ID:9759), may be associated with dampening the early phase of KD.
CSMD1 is located on chromosome 8, in a region that is hypervariable
in humans and which contains numerous immune-related genes [39].
Activation of the classical complement pathway occurs in acute KD
[40], and CSMD1 (NP_150094) is a complement regulatory protein
that blocks the classical but not alternate complement pathway [41].
The functions of other fine-mapped genes are generally poorly
understood. The most significantly associated gene (NAALADL2,
N-acetylated alpha-linked acidic dipeptidase-like 2), which also
showed the greatest change in transcript levels between acute and
convalescent KD, is a large gene of 32 exons spanning 1.37 Mb.
NAALADL2 undergoes extensive alternative splicing leading to
multiple 59 and 39 untranslated regions and variable coding
sequences. Its function is largely unknown, but mutations in the
gene may contribute to Cornelia de Lange syndrome (OMIM:
122470) [42].
Overall we have identified five genetically associated genes that
also had significantly reduced transcript levels during acute KD,
including three that are closely functionally related (Figure 4),
suggesting that these genes may act together. This novel network may
be distinct for KD as differences in transcript abundance in these
genes have not been previously described as being part of a typical
inflammatory response expressed in blood cells. Pathogen-specific
host responses, identified by relative transcript abundance in the
blood have been described for other infectious diseases [43].
Investigation of transcriptome abundance in whole blood rather
than specific cell populations allows assessment of the entire
peripheral blood transcriptome [43] and may be particularly
informative in diseases such as KD, where an infectious trigger is
implicated but remains unidentified [1]. In a genome-wide gene
expression study of KD, variation in neutrophil and lymphocyte
numbers, characteristic of acute KD [44,45], were thought to
account for approximately half of the variation in transcript
abundance during the course of the KD illness [16]. Although we
did not investigate individual cell populations in the current study,
the data suggest that relative changes in transcripts reflect
qualitative as well as quantitative differences. Given the enrichment
of the expression profile with immune-related genes (selected on the
basis of associated loci), the changes in mRNA may not be more
numerous than those expected by chance and do not provide
definitive proof for the gene-specific associations. While the number
of subjects in our expression study is large enough to identify overall
trends in the host response during KD, we are unable to comment
on expression-related allelic association, which will be investigated
in future studies. There is a suggestion from peripheral blood
expression data in KD that ‘person-specific’ gene expression
patterns, possibly reflective of underlying genetic variation, may
be present [16]. Further investigation of the relationship between
genomic associations and gene expression will be undertaken,
although clearly genetic variants may be significantly associated
with disease without resulting in alterations in gene expression.
Our sample of 893 cases represents a large genetic KD cohort
drawn from a single ethnic group. KD shares many features of
other infectious diseases of young children, including fever, rash
and changes to the mucous membranes. There is no diagnostic test
and laboratory parameters individually have insufficient sensitivity
or specificity for diagnosis [1]. In all study cohorts we employed a
conservative and widely accepted KD case definition in an attempt
to maximize phenotypic homogeneity and diagnostic specificity.
The similar ethnicity and ascertainment of KD cases in all cohorts
reduces the risk of spurious associations [15].
Our methodological approach is consistent with current best
practice recommendations in GWAS design and analysis, which are
aimed to identify robust associations and reduce type 1 errors [15]:
(i) the discovery and replication cohorts were recruited using very
similar ascertainment techniques and drawn from predominantly
Caucasian populations, with careful analysis to exclude cryptic
population admixture in the discovery phase, which used a case-
control design; (ii) the variants selected for replication were
predominantly selected using single-point analysis, although we
employed other models, including haplotypic analysis to maximize
the informativeness of the initial GWAS data; (iii) we employed
different genotyping technologies in each of the discovery,
replication and fine-mapping stages to reduce spurious associations
arising from genotyping errors; (iv) we limited our replication
genotyping solely to variants identified in the discovery phase, as
additional fine-mapping around associated variants in the replica-
tion phase may increase spurious associations [46]; (v) we used a
staged study design to avoid conservative correction for multiple
statistical comparisons that might mask associations of moderate
effect size in this modestly sized sample; (vi) we present joint analysis
of the discovery and replication data, rather than considering the
replication data in isolation and; (vii) we have fine-mapped variants
with a MAF.0.05 which lie within or close to known genes.
We are aware that the genomic coverage and power of the
discovery phase of the GWAS were limited and calculate that the
initial GWAS had only approximately 50% power to detect an
OR of 2.0 with alpha,0.05. Our relatively modest sample size
reflects the difficulties in recruiting for a relatively rare disease in
which the phenotype is defined clinically. Our approach therefore
aimed to reduce the risk of type I errors by ensuring that a large
and independent replication cohort was included as part of the
initial design, as we did not expect the associated variants to reach
genome-wide significance, given the cohort size in the GWAS
discovery phase [47]. It was therefore expected that neither
previously reported and credible candidate gene associations in
KD, such as IL4 (Gene ID:3565) [48], VEGFA (Gene ID:7422)
[49,50], CCR5 (Gene ID:1234) [51], and MBL2 (Gene ID:4153)
[52], nor the recently reported ITPKC variant [12] were replicated
by the GWAS. Our study has failed to identify these and almost
certainly other as yet unidentified variants that represent
additional major determinants of KD susceptibility.
We have identified a number of novel associated SNPs,
confirmed by fine-mapping, which lie within or close to previously
unrecognized candidates for KD. The effect sizes, independent
verification in different populations, differential transcript abun-
dance and network analyses all indicate that at least a proportion
of these variants represent novel genetic risk factors for KD. Some
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of the associated genes may interact to mediate the deleterious
effects of infection-driven inflammation on the cardiovascular
system. Further characterization of the associated genes and their
functional interactions may lead to the identification of novel
diagnostic and therapeutic targets in KD and may be informative
about early pathogenic processes in other cardiovascular diseases.
Materials and Methods
Study Design
We used a staged study design with an initial GWAS, an exact
replication phase in an independent cohort and subsequent fine-
mapping of common variants lying within or near known genes.
We performed the initial GWAS analysis in a Dutch Caucasian
case-control sample (the ‘discovery phase’) and re-tested the most
significantly associated SNPs and haplotypes in an independent
sample of KD trios from Australia, the US and the UK, using a
different genotyping technology (the ‘replication phase’). Finally, a
fine-mapping stage including sixteen replicated genes was
performed in a subset of samples from discovery and replication
phases, again using a different genotyping platform.
Phenotypic Definition and Case Ascertainment
KD was defined by the presence of prolonged fever, together with
at least four of the five classical diagnostic criteria [53]. Children with
at least five days of fever and two diagnostic criteria with
echocardiographic changes of coronary artery damage during the
acute and/or convalescent phases of KD were also included, as these
coronary artery manifestations are pathognomonic for KD [53].
Details of clinical symptoms of our study group can be found on
Table S5. Cases of incomplete KD, who have fever, less than 4
diagnostic criteria and no coronary artery manifestations (who
constitute approximately 15% of KD cases receiving clinical
treatment [54]), were excluded, to maximise the homogeneity of
the clinical phenotype.
In all cohorts clinical and laboratory data were obtained directly
from patient medical files and supplemented with parental
questionnaires. Phenotypic data were reviewed in all cases by
experienced pediatricians. Ethical approval was obtained from the
appropriate national and regional institutional review boards for
each study population (Academic Medical Center [AMC],
Amsterdam (Dutch cohort), UK Multi-Centre Research Ethics
Committee (UK cohort), each participating tertiary pediatric
hospital’s ethics committee (Australian cohort) and the University
of California at San Diego (US cohort)). Informed consent and
assent as appropriate were obtained from participating families.
Subjects
The initial GWAS was performed on 119 Dutch Caucasian KD
cases and 135 healthy controls. The cases were identified by
collaborating pediatricians and sent for cardiological evaluation
during the acute stage and subsequent follow-up to the AMC. The
controls were unrelated adult Caucasian blood donors residing in
the same geographical area. Ethnicity was determined by self or
parental ethnic identification. Assessment for possible population
stratification was performed with Eigenstrat [14]. Principal
component analysis was applied to the genotype data to infer
the axes of variation. We used the top two principal components to
identify outliers. Any sample with principal component exceeding
six standard deviations from the mean was identified as an outlier.
This process was repeated five times. A lambda genomic control
(lGC), representation of stratification estimated after dividing the
median (chi-square) by 0.456, was calculated before and after
running Eigenstrat. We observed a lGC=1.18 before removal of
potential outliers. After running Eigenstrat (sigma 6.0, 5 iterations,
n = 10 individuals removed) lGC dropped to 1.1. Dividing chi-
square values by lGC we were able to correct for possible existence
of population admixture (Table 2). Sample duplication and family
relationships were assessed by RelPair [55].
A second independent cohort, which consisted of 583 KD-
affected families, including complete and incomplete trios, from
Australia, the US and the UK, was used to replicate the most
significantly associated variants identified in the GWAS. Family
KD cases in each country were identified from pediatric hospital
databases, through KD parent support groups and through media
releases. Biological parents (where available) and unaffected
siblings (to reconstruct missing parental genotypes) were recruited.
A subset of samples from our GWA and follow up cohorts was
genotyped in a fine-mapping experiment. Due to limitations in
DNA template we could include ,85% of the original samples.
However, a new set of 493 samples were added in the case-control
(N= 247) and family-based cohorts (N= 246). A principal
component analysis comparing Hapmap populations with our
cohort was applied to the genotype data of the case-control cohort
to infer the axes of variation (Figure S1). After removal of potential
outliers (N= 113) lGC was 1.06. Allele chi-square values were
divided by lGC and corrected p-values are reported on Table 4.
DNA and RNA Collection and Extraction
Blood was collected into EDTA (Dutch, UK and US cohorts) and
ADC (Australian cohorts, on whom Buffy coats were separated).
Shed buccal cells were collected as previously described [51].
Genomic DNA was extracted by standard protocols. DNA quality
was assessed by visual inspection after running 1.2% agarose gels and
by calculating absorbance ratio OD260 nm/280 nm. DNA quantifica-
tion was measured using Picogreen dsDNA reagent. Degraded
samples or those with low DNA concentration were excluded.
RNA samples from acute KD cases were obtained prior to
intravenous immunoglobulin treatment and again during convales-
cence (within one year n=17, after one year n=10) from 27 US
children who fulfilled the KD case definition. These KD patients
were also analyzed as part of the replication cohort. Whole blood was
collected into the PaxGene tubes, according to manufacturer’s
instructions and RNA was extracted and stored at 280uC for batch
analysis. RNA quantification was performed by optical density
(260 nM).
Genotyping in GWAS and Follow-Up Studies
We genotyped the Dutch case-control samples using the
Affymetrix 250 K NSP chip in accordance with the manufactur-
er’s instructions. Samples with call rates below 93% at p= 0.33
after running a BRLMM algorithm (Bayesian Robust Linear
Model with Mahalanobis distance classifier, Affymetrix), were re-
hybridized and were excluded from further analysis if they failed to
achieve the established threshold.
Associated individual SNPs from the GWAS were ranked by
nominal significance using a combination of allelic association,
Armitage trend test and a recessive-dominant model. SNPs that
deviated significantly fromHWE in the control group after applying
a Bonferroni correction, or failed genotyping QC (call rate,93%,
or monomorphic) were excluded from further analysis. The 1176
most significantly associated SNPs were selected for genotyping in
the Australian, UK and US trios by a custom Illumina Oligo Pool
Assay. For 28 SNPs genotyping assays could not be designed,
leaving 1148 SNPs for the follow-up study. Families were excluded if
no familial relationship was detected by RelPair [55], if there was
sample duplication, if the proband genotype was unavailable or if
they had more than 3 Mendelian errors. Analysis of the successfully
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genotyped SNPs was performed with Illumina BeadStudio software.
In addition, haplotypic analysis of the GWA data was performed,
using a multi-marker sliding window [56]. Genotyping of all 166
SNPs identified by haplotypic analyses was performed by
Sequenom iPLEX in the family-based follow-up cohort.
Identifying Associated Genes
For each disease-associated polymorphism verified in the follow-
up family study, we investigated whether the variant was within an
annotated gene. When the SNP was in an inter-genic region, we
analyzed the closest annotated genes situated within 50 kb up- and
downstream.
Fine-Mapping of Associated Variants
Replicated polymorphisms with allele frequencies over 5%, located
within genes or five kb up or downstream of a gene were selected for
fine-mapping. Sixteen genes fulfilled criteria (Table S3). Using a SNP-
tagging approach (r2$0.8) we selected 1052 SNPs from Hapmap for
genotyping with Illumina ISelect Infinium. After standard quality
control (call rate,93%, minor allele frequency below 0.01) 1,003
SNPs were included in the association analysis (Table S3).
Gene Ontology Clustering
Associated genes were investigated for gene ontology informa-
tion by Ingenuity Pathways Analysis (IPA) software (Ingenuity
Systems, www.ingenuity.com) using an unsupervised analysis. To
start building networks, IPA queries the Ingenuity Pathways
Knowledge Base for interactions between identified ‘Focus Genes’,
in our case genes detected in the GWAS, and all other gene objects
stored in the knowledge base, to generate a set of networks with a
maximum network size of 35 genes/proteins. Networks are
displayed graphically as genes/gene products (‘nodes’) and the
biological relationships between the nodes (‘edges’). All edges are
supported by at least one reference from the literature, or from
canonical information stored in the Ingenuity Pathways Knowl-
edge Base. In addition, IPA computes a score for each network
according to the fit of the user’s set of significant genes. The score,
representing the –log (p-value), indicates the likelihood of the
Focus Genes in a network from Ingenuity’s knowledge base being
found together due to random chance.
Gene Expression
Genes corresponding to associations or identified by IPA were
investigated for differential expression (between acute and
convalescent KD) using Taqman low density array (TLDA;
Applied Biosystems, Foster City, CA, USA) on 2 mg total RNA as
per manufacturer’s instructions. Briefly, 2 mg total RNA was
reverse transcribed using High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA, USA). Reverse-transcriptase
reaction was performed at 25uC for 10 min and then 37uC for
2 hours followed by 85uC for 5 seconds. cDNA converted from
0.1 ug RNA was resuspended in 50 ml buffer and was added to
50 ml TaqMan Universal Master Mix (26) (Applied Biosystems)
then immediately loaded into a Micro Fluidic Card (3M
Company, Applied Biosystems). The card was spun twice at
1200 rpm for 1 min each time to distribute the PCR mix into the
wells of the card before sealing and loading into the ABI 7900HT
sequence detection system. Default thermal cycling conditions
were used (50uC for 2 min with 100% ramping, 94.5uC for 10 min
with 100% ramping, and finally 40 cycles of 97uC for 30 sec with
50% ramping and 59.7uC for 1 min with 100% ramping) and data
were normalized for RNA loading levels by using 18 s quantitation
as a reference and exported using SDS RQ Manager software
(Applied Biosystems, Foster City, CA, USA). Relative (RQ) levels
were exported and analyzed for significance using the Wilcoxon
Rank Sum Test (assuming the data are non-normally distributed).
Fold-change analysis was based on median levels for the acute
stage samples over the convalescence samples.
Statistical Analyses
In the initial GWAS, HWE in the control group and allelic
association analysis were calculated using HelixTree v4.4.1 (Gold-
enHelix Inc., Bozeman, MT, United States) and Exemplar (Sapio
Sciences, LLC, York, PA, United States). Allelic P-values were
calculated by means of a 262 chi-square table and an Armitage trend
test was used to derive genotypic p-values. Genotype association
analysis and odds ratios were calculated using Exemplar. A two-sided
Fisher’s exact test was used when counts in any cell fell below five.
Allelic analysis of the X chromosome SNPs was performed with
Haploview v3.31 [57] and a likelihood ratio test was applied to calculate
genotypic associations. Quantile-quantile (Q-Q) plots were construct-
ed by ranking a set of values of –log p-value and plotting them against
their expected values. Deviations from the line of equality indicated
either that the theoretical distribution was incorrect, or that the
sample was contaminated with values generated in some other
manner (for example, by a true association). The family-based
association analysis was performed using FBAT [58], allowing
transmission disequilibrium analysis in extended families. Combined
p-values and odds ratios were calculated by Fisher’s combined
probability test which allows pooled information across several tests
that share the same null hypothesis [59]
Haplotypic Analysis
Analysis of haplotypic associations was performed using a
recently described method, the VSSWRR (Variable-Sized Sliding
Window via Regularized Regression), a haplotype analysis method
for population-based case-control association studies [56]. It uses a
variable-size sliding window where the maximum window size is
determined by local haplotype diversity and the sample size and a
combined analysis of all the haplotypes of different lengths (up to
the maximum window size) at the same starting position is
performed using L1-regularized regression method, adjusting for
the dependency and complementariness among the haplotypes. It
allows efficient management of a large number of haplotypes and
is powerful in the detection of disease associations [56].
We used the Haplotype Relative Risk (HRR) method for testing
for LD between marker genotypes and disease phenotypes for the
trios (affected offspring and parents) in the fine-mapping study design
[60]. For testing LD this method compares the transmitted parental
alleles to affected offspring to those which are not transmitted. In
many of the genetic association studies complete genotypes for both
the parent may not be available. Hence to use partial information
available in the affected child in trios in which both single and two
parent genotypes are missing, Guo et al (2005) extended the HRR
methods using Expectation Maximization (EM) algorithm. Assuming
that the parental genotypes are missing at random they use EM
algorithm to estimate the proportion of parents who transmitted a
specific allele and non-transmitted the other allele. If there is not a
severe admixture among the families, through simulations Guo et al.
(2005) have demonstrated that the EM-HRR gained power by
including the families with the affected child for which single or both
the parental genotypes are missing [61].
Supporting Information
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(206 individuals). A principal component analysis comparing
Hapmap populations with our cohort was applied to the genotype
data of the case-control cohort to infer the axes of variation
showing our study group (light blue and light orange dots)
clustering with CEU population (yellow dots) and clearly separated
from Asians (dark blue and white dots) and Africans (green dots).
Found at: doi:10.1371/journal.pgen.1000319.s001 (1.94 MB TIF)
Figure S2 Linkage Disequilibrium Plot of a Region Containing
the Most Significant P-values of ZFHX3. The upper portion shows
-log (p-values). SNPs in high LD (r2.0.8) with polymorphisms in
our initial GWA are highlighted with blue boxes and blue dots. D9
values indicate inside each diamond. Red diamonds without a
number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s002 (4.16 MB TIF)
Figure S3 Linkage Disequilibrium Plot of a Region Containing
the Most Significant P-values of DGKB. The upper portion shows -
log (p-values). SNP replicated from our initial GWA (rs196751) is
highlighted with a blue box and blue dot. D9 values indicate inside
each diamond. Red diamonds without a number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s003 (4.01 MB TIF)
Figure S4 Linkage Disequilibrium Plot of CAMK2D. The upper
portion shows -log (p-values). D9 values indicate inside each
diamond. Red diamonds without a number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s004 (0.73 MB TIF)
Figure S5 Linkage Disequilibrium Plot of CSMD1. The upper
portion shows -log (p-values). D9 values indicate inside each
diamond. Red diamonds without a number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s005 (0.08 MB TIF)
Figure S6 Linkage Disequilibrium Plot of LNX1. The upper
portion shows -log (p-values). D9 values indicate inside each
diamond. Red diamonds without a number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s006 (0.21 MB TIF)
Figure S7 Linkage Disequilibrium Plot of PPPR114C. The
upper portion shows -log (p-values). D9 values indicate inside each
diamond. Red diamonds without a number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s007 (0.52 MB TIF)
Figure S8 Linkage Disequilibrium Plot of TCP1. The upper
portion shows -log (p-values). D9 values indicate inside each
diamond. Red diamonds without a number represent D9=1.
Found at: doi:10.1371/journal.pgen.1000319.s008 (0.04 MB TIF)
Table S1 Chromosomal Location and Allele Frequencies of
1,116 Genotyped SNPs in the Follow-Up Study.
Found at: doi:10.1371/journal.pgen.1000319.s009 (0.17 MB
XLS)
Table S2 Chromosomal Location, Allele Frequencies and
Haplotype Blocks of 137 Genotyped SNPs in the Follow-Up
Study Derived from Haplotype Analysis.
Found at: doi:10.1371/journal.pgen.1000319.s010 (2.44 MB
XLS)
Table S3 Chromosomal Location, Gene and Consequence of
1,003 SNPs Successfully Genotyped in Fine-Mapping Stage.
Found at: doi:10.1371/journal.pgen.1000319.s011 (0.12 MB
XLS)
Table S4 Associated Allele, Minor Allele Frequencies in
Selected Populations and Ancestral Alleles of 46 Associated SNPs
from the Fine-mapping Stage.
Found at: doi:10.1371/journal.pgen.1000319.s012 (0.03 MB
XLS)
Table S5 Detailed Description of Patients Fulfilling Classical
Symptoms in Kawasaki Disease (individuals are included only if
complete clinical data were available).
Found at: doi:10.1371/journal.pgen.1000319.s013 (0.02 MB
XLS)
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